De novo mutations (DNMs) are being increasingly recognized as causal factors for rare diseases. Identifying rare DNM carriers will allow researchers to study the likely distinct molecular mechanisms of DNMs. We developed Famdenovo to predict DNM status (DNM or familial mutation, FM) of deleterious autosomal dominant germline mutations for any syndrome. We introduce Famdenovo.TP53 for Li-Fraumeni syndrome (LFS) and analyze 324 LFS family pedigrees from four US cohorts: a validation set of 186 pedigrees and a discovery set of 138 pedigrees. The concordance index for Famdenovo.TP53 prediction was 0.95 (95% CI: [0.92, 0.98]). Forty individuals (95% CI: [30, 50]) were predicted as DNM carriers, increasing the total number from 42 to 82.
Introduction
De novo mutations (DNMs) are defined as germline variants (mutations) occurring in the carrier, but not in either of the carrier's parents (Rahbari et al. 2016) . In humans, dozens of DNMs (Conrad et al. 2006; Kondrashov 2003; Kong et al. 2012; Lipson et al. 2015; Lynch 2010; Nachman and Crowell 2000) occur throughout the genome of each newborn. DNMs are considered a major cause for the occurrence of rare early-onset, reproductively lethal diseases (Acuna-Hidalgo et al. 2016) . Initial analyses have shown that the rate of germline DNMs increases with paternal (Kong et al. 2012 ) and maternal age (Wong et al. 2016) ; plus, DNMs are correlated to a number of factors (Battle and Montgomery 2014), including the time of replication (Francioli et al. 2015) , the rate of recombination (Francioli et al. 2015) , GC content (Michaelson et al. 2012) , and DNA hyper-sensitivity (Michaelson et al. 2012) . DNM carriers and their associated factors have always been a focus of genetics research because of their crucial role in the evolution of species (Goldmann et al. 2019) .
Not only are DNMs the raw materials of evolution, but they may also shape and determine disease susceptibility (De Ligt et al. 2012; De Rubeis et al. 2014; Iossifov et al. 2014; Krumm et al. 2015; Robinson et al. 2014) . DNMs have been recognized as causal factors for rare diseases, such as hereditary retinoblastoma (Dryja et al. 1997) , epileptic encephalopathies (Allen et al. 2013) , Bosma arhinia microphthalmia syndrome (Gordon et al. 2017) , ubiquitin-proteasome system-dependent disorders (Küry et al. 2017) , and neurodevelopmental diseases, including intellectual disability, autism and schizophrenia (Katrancha et al. 2017 ). In the near future, as more whole-genome or whole-exome sequencing of individuals with various disorders and their relatives in different populations become available, it is likely that more DNMs will be identified as associated with disease outcomes. These mutations, although individually rare, may capture a significant part of the heritability for complex genetic diseases that is not detectable by genome-wide association studies.
DNMs play an important role in hereditary cancer syndromes, such as retinoblastoma and Neurofibromatosis, where the de novo rates are as high as ~90% (Dryja et al. 1997 ) and ~50% (Evans et al. 2010; Jett and Friedman 2010) , respectively.
Other hereditary syndromes have lower de novo rates. For example, Li-Fraumeni syndrome (LFS) is an autosomal dominant cancer predisposition syndrome that commonly manifests as soft tissue and bone sarcomas, breast cancer, brain tumors, leukemia, and adrenal cortical carcinomas (Olivier et al. 2003; Nichols et al. 2001) . LFS is associated with germline mutations in the TP53 tumor suppressor gene (Malkin et al. 1990; Correa 2016) , of which 7% -20% are de novo (Gonzalez et al. 2009 ). Clinically, it is of interest to identify de novo carriers of a TP53 germline mutation, who may otherwise go unnoticed until they or their offspring develop multiple cancers. Identifying these carriers allows them to undergo LFS screening and surveillance protocols.
Understanding the cause of de novo mutations in cancer genes like TP53 will help develop strategies for early identification and will have a novel and significant impact on the field of human genetics.
Predicting a DNM in a gene is not trivial when the parental mutation statuses are unknown. Incomplete family history may skew observational criteria and the prediction may suffer from low sensitivity and specificity. Mendelian risk prediction models (Chen et al. 2004 ) have been used successfully for accurate prediction of deleterious mutation status in familial breast and ovarian (Euhus et al. 2002) , bowel (Chen et al. 2006b ), pancreatic (Wang et al. 2007 ) cancers, melanoma (Wang et al. 2010) , and most recently in LFS (Peng et al. 2017; Renaux-Petel et al. 2018) . Using LFS family pedigree cohorts that include cancer history as a case study, we developed a novel statistical approach, Famdenovo, to predict the DNM status, i.e., whether the carrier's deleterious mutation is familial or alternatively arose from a new mutation during meiosis or mitosis. Famdenovo was developed as a freely available R package and Shiny web app (http://bioinformatics.mdanderson.org/main/Famdenovo).
DNMs are rare, and therefore require a large amount of high-quality data to be studied thoroughly. We introduce Famdenovo.TP53, which was modeled and validated on a large cohort consisting of 324 LFS family cohorts that were collected from four major cancer centers in the US, with TP53 genetic testing results available in at least one trio per family. Our method consisted of a large-scale validation of the performance of Famdenovo.TP53 using families with LFS, in which the de novo status of TP53 mutations are known, as well as an application of Famdenovo.TP53 to identify potential DNMs in TP53. The computer-based and data-driven identification of deleterious DNM carriers in TP53, who are otherwise hidden in a wide population, enabled a new perspective of DNMs that is gene and disease-centric. In addition, we introduce Famdenovo.brca for hereditary breast and ovarian cancer syndrome (HBOC), and apply it to a small set of family data from the Cancer Genetics Network (CGN).
Results

Famdenovo for predicting the deleterious DNM status among mutation carriers
Famdenovo is based on widely-used Mendelian models (Chen et al. 2004 (Chen et al. , 2006b Parmigiani et al. 1998; Wang et al. 2007 Wang et al. , 2010 and calculates the probability that a deleterious germline mutation is de novo. The de novo probability of interest can be written as the Pr(father is a noncarrier, mother is a noncarrier | child is a mutation carrier, family history). We calculate this probability as a function, g(c, f, m), of pedigree-based carrier probabilities for the child (c), father (f) and mother (m), respectively. We derived the g() function using Bayes' rule (as detailed in the Methods section), and obtained input values using Mendelian models as the corresponding marginal probabilities for one individual's c, f, and m, respectively. Each of the marginal probabilities is calculated using the Elston-Stewart algorithm (Fernando et al. 1993) . Famdenovo then applies Bayes' rules to estimate de novo probabilities in deleterious mutations. Similar to previous developed Mendelian models, Famdenovo can be adapted for specific diseasegene associations by setting its input parameters: the penetrance of the disease-gene, the allele frequency of the gene(s), and the de novo mutation rate. We have incorporated well-validated parameter estimates in Famdenovo.TP53 for LFS-TP53 (Peng et al. 2017) and Famdenovo.brca for HBOC-BRCA1/2 (Chen et al. 2006a; Parmigiani et al. 2007) .
Based on the validation study and a sensitivity analysis in the LFS cohort data, we recommend classifying individuals with de novo estimated probability greater than 0.2 as DNM carriers. The family-wise de novo probability is defined to be the largest de novo probability of all the family members, accounting for the fact that children of de novo carriers may carry familial mutations. We classify a family as de novo if they present a family member with a de novo probability that is above the 0.2 cutoff.
Figure 1. Illustration of clinical counseling using Famdenovo based on family
history. The number below each individual is the age at last contact (healthy or affected with cancer). The arrow points to the counselee who is known to be a TP53 mutation carrier. The de novo probabilities shown are given by Famdenovo.TP53. (A) A pedigree with four cancer patients. (B) A pedigree with three cancer patients. (C) A pedigree with two cancer patients. Figure 1A shows a pedigree with four cancer cases: two soft tissue sarcoma (STS) at 25 and 27 years old, one breast cancer at 40 years old, and another STS at 20 years old. The arrow points to the counselee who is a TP53 mutation carrier, and the probability of the mutation being de novo for the counselee is 0.0033, which is below the 0.2 cutoff. As the probability is below the cutoff, Famdenovo.TP53 predicted that this mutation is not de novo. Based on pedigree analysis, it is likely that this is a familial mutation inherited from the proband's mother. Figure 1B shows a similar pedigree with three cancer patients, with one less affected relative in the maternal branch of the counselee compared with Figure 1A , and with an older age of diagnosis for the counselee's mother, which increases the predicted probability of the mutation being de novo. The de novo probability given by Famdenovo.TP53 is 0.47, which is greater than the 0.2 cutoff. As the probability is above the cutoff, Famdenovo.TP53 predicted this mutation to be a DNM. Figure 1C shows a similar pedigree with only two cancer cases in the counselee and counselee's offspring, compared with Figure 1B . Because there were no longer any cancer patients in the older generations and the counselee's siblings were all healthy, it was very likely that this mutation was de novo. The probability of the mutation being de novo was 0.89, which was much greater than the 0.2 cutoff, so Famdenovo.TP53 predicted this mutation to be a DNM.
Validation of Famdenovo.TP53 in individuals with known DNM status in TP53
We evaluated the performance of Famdenovo.TP53 based on germline TP53 tested individuals with known DNM status from the four cohorts (Figure 2) . Among the 324 LFS family pedigrees we collected, 186 families had a known DNM status and 138 had an unknown DNM status (Figure 2) . Table 1 provides a summary of the demographics for all four study cohorts. The largest set of DNM carriers was contributed by the MD Hospital of Philadelphia or CHOP) in our study. A subset of families within each cohort have mutation testing results from the parents, and therefore the true DNM status is known. These families form the validation set of our study. In the other families, the family members' DNM statuses are unknown, and they form the discovery set. We used observed:estimated ratios (OEs) and receiver operating characteristic (ROC) curves to evaluate the calibration and discrimination of our model. Figure 3 shows the ROC curves for the validation set from the four cohorts combined. The orange stars represent the result of Criterion 2 at a cut-off age (provided next to the stars). The gray dotted lines show the range of cut-off ages, 45 to 65, where a partial AUC will be calculated for Criterion 1. We also compared our method with two simple criterion-based prediction models that do not require the collection of extended pedigree data. Criterion 1 predicts a mutation to be de novo if the mutation carrier does not have a parent diagnosed with cancer before a cut-off age, e.g., 45 or 60. Criterion 2 predicts a mutation to be de novo if, in addition to criterion 1, neither of the grandparents was diagnosed with cancer before the cut-off age. Criterion 1 is more relaxed than Criterion 2. Figure 3 shows that both criteria (over a range of cut-off ages) fall outside of the 95% confidence interval band of our method. Neither of the criteria is able to reach the full range of the ROC curve. Criterion 2 follows the same trend as criterion 1, but it is less sensitive and only slightly more specific. Moreover, for each criterion we calculated a partial AUC area with cutoff ages from 45 to 65, which were then rescaled to the full range of 0 to 1. The rescaled AUC for Criterion 1, the better performing of the two criteria, is still much lower than Famdenovo.TP53, with a difference of 0.14 (95% CI: [0.054, 0.20]) ( Table 2 ). Our results demonstrate that Famdenovo.TP53 outperforms criterion-based prediction models and that extended pedigrees with cancer diagnosis information are needed for the accurate identification of DNM carriers.
We evaluated the sensitivity and specificity of Famdenovo.TP53 under various prediction cutoff values using the validation set ( Supplementary Table 2 ) in order to identify an optimal classification cutoff. If the predicted probability was equal to or above the prediction cutoff, the individual was classified as a DNM carrier. As the cutoff probability increases, the sensitivity decreases and specificity increases. We chose a cutoff of 0.2, which provided a good tradeoff of a sensitivity of 0.76 and a specificity of 0.93. Maintaining a high specificity is essential to allow for downstream clinical interpretation of de novo mutations. Using the observed 25% for deleterious DNMs in our TP53 clinical cohorts, we estimated that Famdenovo.TP53, at a cutoff=0.2, will achieve a positive predictive value (PPV) of 0.78 and a negative predictive value (NPV) of 0.92. Without using pedigree information and model-based analysis like
Famdenovo.TP53, like Criterion 1, will only achieves a PPV of 0.63 and an NPV of 0.92 (cutoff age=65, sensitivity=0.8, and specificity=0.8).
We also conducted a sensitivity analysis to evaluate how the pedigree size affects the validation results. The range of pedigree sizes for each of the four cohorts is listed in Figure 1) . We divided the 186 families in the validation dataset into two groups: large families and small families, using the median size of all families (n = 29) as the cut-off size. We obtained similar results under the two Table 3 ).
Discovery in individuals with unknown DNM status using Famdenovo
We applied Famdenovo.TP53 to the 138 families with unknown DNM status in the discovery set from the same four cohorts. Figure 4 provides the number and percentage of predicted DNM carriers at a cutoff of 0. 
Association of deleterious DNMs in TP53 with clinical outcomes
Combining the validation and discovery sets resulted in a total of 82 DNMs from 82 families and 450 FMs from 242 families, which equipped our study with a sample size that was meaningful to evaluate associations between mutation status and a diverse range of individual outcomes: sex, cancer types, multiple primary cancers, age-of- Table 5 ). All but two DNM carriers were probands. Therefore, we infer the previous significant finding was due to an imbalanced addition of FM carriers, who were relatives of the probands, to the female and male categories, i.e., a numerical artifact. In the following association analyses, we present comparisons within the probands only.
Next, we asked whether the DNM status was associated with breast cancer. Among 233 probands with cancer information ( Supplementary Table 6A Figure 3 shows the distributions for the validation and discovery sets, respectively presented in females (n=4, mutation type: p.G245S, p.S127F, p.R337H, Supplementary   Table 10 ) and not males. For leukemia, DNMs also were only presented in females (n=2, mutation type: R282W, Supplementary Table 9 ). We found no difference in ages of diagnosis between DNM and FM carriers across cancer types, including breast cancer ( Figure 5A) .
Parental ages. We also investigated whether the parental ages (paternal or maternal) were different among TP53 DNM and FM carriers. Parental age refers to the age of the parent at the time of child birth. Literature on the origins of DNMs suggested their occurrence rate across the genome was correlated with paternal age (Kong et al. 2012 Supplementary Table 10 ). In particular, p.R248W mutations were missing among the DNMs list for this study. Interestingly, among the FMs, p.R248W was as prevalent as p.R248Q (n=7 vs. 9 out of 242, Figure 6B ). The observation of n=0 out of 82 DNMs for p.R248W was marginally significant (p-value=0.09, based on a Poisson distribution). The cancer types of FM-p.R248W carriers encompass the cancer spectrum of LFS, including breast cancers. The frequencies of DNMs at different amino acid positions (Figure 6C and Figure 6D ) did not differ significantly in the validation and discovery sets, supporting the validity of predicted DNMs in the discovery set.
Deleterious DNM status among mutation carriers in BRCA1/2.
We used a dataset with 39 extended pedigrees from Cancer Genetics Network (Anton-Culver et al. 2003) : 23 families had BRCA1 mutation carriers, and 16 families had BRCA2 mutation carriers. Among them, we predicted a total of 7 (17.9%) DMNs using a cutoff of 0.2. Among the 7 predicted DMNs, 4 people (17.4%) were BRCA1 mutation carriers, and 3 people (18.8%) were BRCA2 mutation carriers. Visual inspection of the family cancer history of these 7 families (Supplementary Figure 2) supports the validity of the Famdenovo predictions. Due to lack of genetic testing information of both parents, we were limited to positive testing results from some parents, which provided us with a small set of true negatives for validation. A total of 8 people from 6 families were confirmed to be FMs. The y axis is the count of DNMs. The x axis represents the amino acid positions.
Discussion
Deleterious germline DNMs are more prevalent than previously thought. For cancer genes such as TP53, we estimated a ~1:1 ratio of deleterious DNMs compared to FMs in our LFS cohorts, supporting the importance to study its etiology. To enable future genomic studies, we have developed a statistical method and tool, Famdenovo, to predict the deleterious DNM status in cancer genes using family history data. was not observed in DNMs, but was prevalent in FMs.
The observed discrepancy in frequency of p.R248W in DNMs versus FMs, but not in p.R248Q, is consistent with the literature on functional differences in the two mutations (Walerych et al. 2012) . When mutated in cancer cells, p.R248W has recently been reported to induce a much stronger response from T cells than p.R248Q (Malekzadeh et al. 2019 would be useful to predict DNMs. Identification of patients with DNMs in order to study them collectively will further our understanding of the molecular mechanism underlying deleterious DNMs and is essential for future identification of the hidden DNMs for genetic testing.
Missing data in parental genotypes is more prevalent in HBOC cohorts, hence restricting us from conducting an extensive validation of Famdenovo.brca. Genetic counselors suggested that it is likely because the parents of BRCA1/2 mutation carriers are generally at much older ages when they entered a study, hence at a higher frequency of loss to follow-up, as compared to parents of TP53 mutation carriers (commonly childhood cancer patients).
We remain cautious with the downstream interpretations of Famdenovo predicted DNMs, or to a larger extent any other biological factors that may confound our interpretation. We enumerate the following four considerations in the context of TP53, which are applicable to other genes of interest in future. First, mosaicism in parents could be partially contributing to DNMs in the children (Renaux-Petel et al. 2018 ). If a parent presents an LFS-like phenotype due to a mosaic TP53 mutation,
Famdenovo.TP53 would consider the parent as a germline mutation carrier, hence deducing the child to be an FM carrier. The DNM status of a child under this condition would then be missed by Famdenovo.TP53. Such a condition is rare, at ~5% (Renaux-Petel et al. 2018), and of less concern to clinical practice as this population is already targeted by genetic testing. Patients with an LFS-like phenotype are often tested, first with Sanger sequencing, then with NGS at high depth, until mosaicism is confirmed.
Second, somatic clonal expansion in cancer patients may create a look-alike germline TP53 mutation, resulting in a false positive in DNM status. However, such observation was reported in a general panel-testing population, which is supposedly >99.9% without TP53 mutations, hence presenting an expected low positive predictive value (Weitzel et al. 2018) . By focusing on clinically ascertained families, we do not expect aberrant clonal expansion to be the cause of the identified DNMs. Furthermore, we only observed 2 DNM carriers who have ever had leukemia, a cancer type known to present clonal hematopoiesis. Third, Famdenovo.TP53 assumes the mutations are deleterious and their effect on cancer outcomes follow the penetrance curves previously estimated from a set of families with LFS. Variants with unknown significance in TP53 were excluded from the study. Last, DNMs across the genome were reported to be shared in siblings (Jónsson et al. 2018) . Within a single gene like TP53, however, we did not observe sibling sharing.
Because of our study design, distinct from existing DNM studies that are genomewide and across many individuals, we are limited to a small number of mutations, which even with Famdenovo's discovery set is still too small to perform sequence contextbased analyses that would follow those existing DNM studies. In contrast, what existing studies cannot provide is a laser-beam view of the impact of de novo mutations in a single gene and a single disease syndrome. Both study designs should be carried out in order to provide a well-rounded understanding of de novo mutations.
In summary, we present a new epidemiological study design, enabled by a statistical method called Famdenovo, to evaluate the clinical impact of deleterious de novo mutations in cancer genes. We introduce both Famdenovo.TP53 and Famdenovo.brca and illustrate both models using family history cohorts. This study design is important for future genetic research, as well as the clinical management of patients and their families as we learn new biology and associated clinical risk for DNM carriers. Famdenovo is freely available at http://bioinformatics.mdanderson.org/main/Famdenovo.
Methods
Model development
Famdenovo estimates the probability of de novo mutation in any designated family member who carries a deleterious germline mutation in a given gene, based on a detailed family disease history and values of genetic parameters, such as the penetrance and prevalence, for the gene and the corresponding diseases. The prevalence for gene mutations is expressed as Pr(G), where G denotes genotype, which could be wildtype (denoted as 0), a heterozygous mutation (denoted as 1), or a homozygous mutation (denoted as 2). Pr(G) for three genotypes can be derived from the prevalence of the mutated alleles using the Hardy-Weinberg equilibrium. The penetrance is the probability of developing the disease at a given age for individuals who carry the germline mutations. The disease of interest is an inherited syndrome, such as Li-
Fraumeni syndrome or HBOC. The genes (one or more) of interest are those that are known to be the major cause of the corresponding inherited syndrome when they are mutated. The germline mutations here correspond to deleterious mutations that are accepted in clinics as mutations that would categorize the carriers as high risk for developing the disease in the future and who will be suggested to adhere to a series of cancer prevention protocols. Other mutations in these genes, including those that are variants of unknown significance, are considered as wildtype in the model. Either dominant or recessive mode of inheritance can be assumed in Famdenovo.
Let P be the pedigree information of the family (e.g., the pedigree drawn in Figure   1 ), let D be the disease phenotype information of all family members, and GC be the genotype of the carrier, then the probability of the mutation being de novo can be written as Pr( is | is germline, , ), referred to as the "de novo probability."
To calculate Pr( is | is germline, , ), we have the following equation:
Pr( is | is germline, , ) = Pr� = 0 ∩ = 0 � = 1, , ) = Pr( = 1| = 0, = 0, , ) × Pr� = 0 | , � × Pr ( = 0 | , ) Pr ( = 1 | , )
where G m is the genotype of the mother and G f is the genotype of the father. In equation (1), all four probabilities are usually difficult to obtain through direct calculations. Hence, we apply Mendelian models to derive them. Let the family cancer history = ( , ). In a Mendelian model, the probability of the person's genotype given the family cancer history Pr( 0 | ) is the updated population prevalence Pr ( 0 ) by incorporating family cancer history H. Here, 0 denotes the genotype of the person of interest, which can be , or . We can estimate it via the following formula.
In equations 2 and 3, n is the total number of the counselee's relatives within a family.
Pr ( | 0 ) is the probability of the phenotypes for the whole pedigree given the genotype of the counselee, which is the weighted average of the probabilities of family history given each possible genotype configuration of all relatives Pr ( | ). The weights are the probabilities of the genotype configuration based on Mendelian transmission. Pr ( | )
are products of the individual probability distributions of penetrance Pr ( | ) when we assume conditional independence. With the equations above for Pr ( 0 | ), we can then calculate the four probabilities in equation (1), respectively, by assigning the right person as 0 and assuming known genotype status in the parents, when needed.
The posterior probability calculation is performed using the Elston-Stewart, or peeling algorithm. This algorithm characterizes Mendelian transmission using a transmission matrix of the probability of the genotype for an individual given the genotypes of the father and mother, Pr ( | , ) (Fernando et al. 1993) .
With the calculated probabilities, we classify the DNM status based on a cutoff on the probability. Pr( is | is germline, , ) ≥ are identified as DNM carriers. We used the validation data in this study to determine an ideal cutoff.
Parameter settings: penetrance and prevalence. Famdenovo.TP53: We used a previous penetrance estimate for TP53 mutation carriers and noncarriers from six large pediatric sarcoma families at The University of Texas MD Anderson Cancer Center, which are not included in this study (Wu et al. 2006) . We assumed the TP53 mutation follows Hardy-Weinberg equilibrium, but this could be modified by user's input when homozygous genotype information is published. The mutation prevalence, i.e., allele frequency, is specified as 0.0006 for pathogenic TP53 mutations, which was derived in our previous study (Peng et al. 2017 were previously validated using external study cohorts that are different from the study cohorts in this study (Peng et al. 2017 ).
Famdenovo.brca:
We used previous externally validated penetrance estimates of BRCA1 and BRCA2 mutations of the US population for both Ashkenazi Jewish (AJ) and non-AJ families Chen et al. 2006a ). We used 0.00305 and 0.0034 as the mutation allele frequencies for BRCA1 and BRCA2, respectively. We assumed a 10% DNM rate among all mutations. The allele frequency and DNM rate are priors that are then updated by family history to generate a posterior probability. The same cutoff value 0.2 was used to classify DNMs in BRCA1/2.
Study cohorts
We evaluated our method on TP53 using four cohorts ( Supplementary Table 1 ).
(A) Families with LFS primarily ascertained through clinical criteria were included in the MDA cohort. Details on data collection, specific cancers, and germline testing for this cohort have been published (Shin et al. 2020) . This cohort has 82 families with known de novo status and 58 families with unknown de novo status. (B) The National Cancer Institute (NCI) LFS cohort (NCT01443468), our second cohort, is from a long-term prospective, natural history study that started in 2011 (Mai et al. 2016 ). The cohort includes individuals meeting classic or Li-Fraumeni-like diagnostic criteria, having a pathogenic germline TP53 mutation or a first-or second-degree relative with a TP53 mutation, or having a personal history of choroid plexus carcinoma, adrenocortical carcinoma, or at least three primary cancers (Birch et al. 1994 
Mutation testing
For the MD Anderson cohort, peripheral blood samples were collected after informed consents were obtained. The probands' TP53 mutation status was determined by PCR sequencing of exons 2-11 (Hwang et al. 2003) . At MD Anderson Cancer Center, when a TP53 mutation was identified, all first-degree relatives of the proband (affected and unaffected by cancer) and any other family member at risk of carrying the familial mutation were tested. Extending germline testing based on mutation status and not on phenotype of family members should not introduce ascertainment bias during analysis (Wu et al. 2006; Katki et al. 2008) . Individuals unavailable for testing (largely deceased) linked to mutation carriers were considered as obligate mutation carriers. No other family member was tested when the proband tested negative.
For the NCI cohort, copies of the clinical TP53 test reports were obtained and verified by the study team for those tested prior to enrollment. For individuals actively participating in the protocol and not previously tested, clinical genetic testing was performed after enrollment. All at-risk family members of individuals who tested positive for a mutation (either prior to enrollment or on study) were offered the option of having site-specific testing through the study. No testing was offered to relatives if the proband tested negative for a TP53 mutation. Additionally, high resolution melt analysis and multiplex ligation-dependent probe amplification were performed in the NCI cohort to detect large deletions or genomic rearrangements.
For the DFCI cohort, the patient information was collected by searching through the Clinical Operations and Research Information System (CORIS) database at the Dana Farber Cancer Institute. The classic (Li and Fraumeni Jr. 1969 ) and updated Chompret (Tinat et al. 2009 ) criteria were applied for selecting eligible families. The methods for TP53 testing were further described in a previous study from DFCI (Rath et al. 2013) .
For the CHOP cohort, pediatric oncology patients were evaluated in the Cancer 
Model evaluation and comparison
In four cohorts (described above) of TP53 mutation carriers with known de novo status, we used Famdenovo.TP53 to calculate the de novo probability for each individual. Because mutation carriers within the same family are not independent, we used family-wise de novo probability and status for model evaluation. If a family had at least one family member with a de novo probability that was over the cut-off, they were defined as a de novo family; otherwise they were defined as a familial family.
Validation was performed on 186 families with known DNM status from the four cohorts. We used OEs to evaluate the calibration and receiver operating characteristic (ROC) curves to evaluate our model's discrimination ability. The OE is the ratio between the observed number of de novo TP53 mutations and the summation of the estimated probabilities of de novo TP53 mutations; ideally, the observed number of DNMs equals the estimated number (OE=1). The ROC curve is generated by plotting the true positive rate against the false positive rate at various prediction cutoffs using Famdenovo.TP53.
A high area under the ROC curve (AUC), i.e., concordance index, indicates that we can find a point on the ROC curve for determining the de novo status with a high true positive rate and a low false positive rate.
We also compared our method with the other two criterion-based prediction models.
The partial AUC is rescaled to the full range of 0 to 1 using the following equation:
Finally, 95% CI were obtained by bootstrapping the AUC values of Famdenovo and the AUC or rescaled the AUC of the two criterion-based models.
